Shinobi Therapeutics Inc. has been awarded non-dilutive grant funding of up to $59 million by the Japanese Agency for Medical Research and Development (AMED).
Tiumbio Co. Ltd. has prepared and tested cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer, inflammation and fibrosis.
Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. have divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agents coupled to GTPase KRAS or its mutant targeting moiety through a linker reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has prepared and tested cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Researchers from the University of Brescia have presented the discovery and preclinical characterization of novel fibroblast growth factor (FGF) trap small molecules, being developed for the treatment of multiple myeloma (MM).
Researchers from Shanghai Jiao Tong University and affiliated organizations have presented data from a study that aimed to identify the prognostic markers related to abnormal methylation in ocular melanoma, including uveal melanoma (UM).
Incyte Corp. has synthesized diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
Angel Pharmaceuticals Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
RSS
